Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company
WARRINGTON, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...
COVID-19
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
InflaRx to cover costs of GOHIBIC for patients who are treated in line with its Emergency Use Authorization (EUA) but...
Tonix Pharmaceuticals Announces KOL Webinar to Discuss Positive Phase 3 Fibromyalgia Data, Sponsored by A.G.P.
Webinar to be hosted on January 31, 2024 at 1:00 pm. ETCHATHAM, N.J., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Tonix...
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum
Interim Data Analysis Anticipated in Mid-2024Expects Full Enrollment by Q1 2025 MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics,...
Nicox Provides Fourth Quarter 2023 Financial and Business Highlights
Press Release Nicox Provides Fourth Quarter 2023 Financial and Business Highlights NCX 470 Phase 3 Denali clinical trial 75% randomizedNet...
ReAlta Life Sciences Strengthens Board of Directors with Appointment of Two Accomplished Biotechnology Innovators
New appointments bring deep research and development expertise and technology innovation to support continued advancement of ReAlta’s EPICC Technology PlatformNORFOLK,...
Ainos Announces $1.75 Million Follow-On Funding
The follow-on funding is a draw down from the $10 million private placement agreement entered into September 25 2023.Use of...
Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
Tailored Vaccines: With the AI-Immunology™ enabled discovery of these novel types of cancer vaccine targets, designing personalized and precision vaccine...
IMU Biosciences secures £11.5 million in Series A funding to revolutionise immune powered precision medicine
Board strengthened with appointments of Tim Haines (Abingworth) as Non-executive Chair and Dr Oliver Nussbaumer (co-founder of GammaDelta Therapeutics and...
STERIS to Host a Conference Call for Fiscal 2024 Third Quarter Financial Results on February 8, 2024
DUBLIN, IRELAND, Jan. 23, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it...
Awakn Life Sciences Completes Successful Investigative Study to Establish Dissociative Effect of a Proprietary Sublingual S-Ketamine Oral Thin Film Formulation in Harmful Drinkers
Awakn Designates Program AWKN-002 for Alcohol Use Disorders in the US MarketToronto, Ontario--(Newsfile Corp. - January 24, 2024) - Awakn...
Cosmos Health Completes Acquisition of Cloudscreen, a Cutting-Edge AI Platform; Enters Lucrative $25Bn+ Global Drug Repurposing Market
CHICAGO, IL / ACCESSWIRE / January 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease
225-cm Catheter Length Expands Access Points in Atherectomy Procedures to Help Reduce Access Site Complications and Accelerate Patient RecoveryLATHAM, N.Y.--(BUSINESS...
AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer
First enrollment takes place at Erasmus Medical Center in Rotterdam, Netherlands Erasmus Medical Center Erasmus Medical Center OCALA, Fla., Jan....
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
- 10,000-subject Phase 2b study would evaluate Vaxart’s next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine...
ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024
MADRID, Spain and BOSTON, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical...
Optimi Health Secures Amendment to Increase Quantities Of MDMA, MDA, And 2C-B Under Controlled Drugs And Substances Dealer’s Licence
Strategic licensing plan prepares Company for future regulatory approvalsVANCOUVER, British Columbia, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp....
BerryDunn Restructures Revenue Cycle Management Team to Meet Growing Healthcare Industry Demands
The restructured team brings in-depth knowledge and direct healthcare experience to RCM consulting.PORTLAND, Maine--(BUSINESS WIRE)--BerryDunn, a full-service assurance, tax, and...
Cosmos Health Bolsters Presence in $400Bn+ Global Generic Drugs Market with $3.5M Acquisition of 10-Drug Portfolio
CHICAGO, IL / ACCESSWIRE / January 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified,...
Masimo Announces Reinstatement of Import Ban on Infringing Apple Watches
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI), a global leader in innovative noninvasive monitoring technologies, welcomes the Federal Circuit’s ruling to lift...